Analysts Set Regulus Therapeutics Inc. (NASDAQ:RGLS) Price Target at $10.80

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) have received an average rating of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $10.80.

RGLS has been the subject of a number of research reports. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Regulus Therapeutics in a report on Wednesday. Oppenheimer reaffirmed an “outperform” rating and set a $7.00 price objective on shares of Regulus Therapeutics in a research report on Wednesday, August 14th. Finally, StockNews.com raised shares of Regulus Therapeutics to a “sell” rating in a report on Tuesday, September 17th.

Regulus Therapeutics Stock Performance

Shares of RGLS stock opened at $1.46 on Tuesday. The stock has a market capitalization of $95.58 million, a price-to-earnings ratio of -1.16 and a beta of 1.62. Regulus Therapeutics has a one year low of $1.08 and a one year high of $3.79. The company’s 50-day simple moving average is $1.59 and its 200-day simple moving average is $1.87.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.17) EPS for the quarter, hitting analysts’ consensus estimates of ($0.17). As a group, research analysts forecast that Regulus Therapeutics will post -0.8 EPS for the current year.

Institutional Trading of Regulus Therapeutics

Several hedge funds have recently bought and sold shares of RGLS. NEA Management Company LLC bought a new position in Regulus Therapeutics in the 1st quarter worth about $18,627,000. RA Capital Management L.P. acquired a new stake in Regulus Therapeutics in the 1st quarter valued at approximately $18,000,000. CVI Holdings LLC bought a new stake in Regulus Therapeutics during the 1st quarter valued at $4,050,000. Vanguard Group Inc. boosted its position in Regulus Therapeutics by 158.4% during the 1st quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock worth $2,132,000 after acquiring an additional 453,784 shares during the period. Finally, Bank of New York Mellon Corp bought a new position in shares of Regulus Therapeutics in the second quarter worth $352,000. 92.38% of the stock is currently owned by institutional investors.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.